Pfizer ₹602 Cr Settlement Allowed as Business Expense - ITAT 2026

What Happened?

The Ahmedabad Bench of the Income Tax Appellate Tribunal (ITAT) has delivered a landmark order allowing a multinational pharmaceutical company to claim a ₹602 crore settlement payment to Pfizer as a deductible business expenditure under Section 37(1) of the Income Tax Act 2025. The tribunal also deleted a captive power plant Transfer Pricing (TP) adjustment and restricted the Section 14A disallowance to only dividends earned, providing comprehensive relief across multiple issues.

Background & Legal Context

Understanding Section 37(1) of Income Tax Act 2025:

Section 37(1) allows a deduction for any expenditure incurred wholly and exclusively for the purpose of business or profession. However, Explanation 1 to Section 37(1) specifically denies deduction for any amount expended in connection with the acquisition of a capital asset.

• The Core Issue: The Income Tax Department argued that the ₹602 crore Pfizer settlement was a capital expenditure because it related to patent rights (an intangible capital asset). Under Explanation 1, capital expenditures cannot be deducted in the year incurred; they must be capitalized and depreciated.
• The Company's Stand: The taxpayer contended that the settlement was purely a dispute resolution payment for patent infringement claims, not an acquisition of patent rights or technology.
• ITAT's Reasoning: The tribunal examined the nature and purpose of the settlement and concluded that the payment was compensatory in nature—meant to resolve an existing dispute—rather than an expenditure incurred to acquire or improve a capital asset.

Relevant Legal Framework:

• Section 37(1) and Explanation 1, Income Tax Act 2025
• Section 14A (disallowance of expenditure relating to exempt income)
• Transfer Pricing rules under Sections 92-92F, Income Tax Act 2025
• Principles established under old Section 37(1) of Income Tax Act 1961 (still applicable for interpretation)

Why This Matters: Patent settlement disputes between multinational companies are common in India's pharmaceutical, IT, and biotechnology sectors. The tribunal's distinction between dispute settlement payments and capital expenditure for acquiring assets is crucial for taxpayers dealing with intellectual property issues.

What Does This Mean for You?

For Multinational Companies (especially Pharma & IT):

• Relief on Patent Settlements: You can now claim deductions for settlement payments made to resolve patent infringement or intellectual property disputes, provided you can demonstrate the payment was not made to acquire new patent rights or improve existing ones.
• Documentation is Critical: The ITAT will examine the settlement agreement carefully. Ensure your legal documentation clearly states that the settlement is compensation for dispute resolution, not a license fee or technology transfer payment.
• AY 2026-27 Assessment Implications: If you have pending assessments or appeals for AY 2026-27 involving similar patent settlement claims, this ruling strengthens your position significantly.

For Transfer Pricing Perspective: The tribunal's deletion of the captive power plant TP adjustment indicates a stricter scrutiny of TP adjustments. Multinational companies must ensure their TP documentation is robust and aligned with the arm's length principle under Section 92.

For Section 14A (Dividend Disallowance): The tribunal restricted the Section 14A disallowance to only dividends actually earned, not to the entire investment or potential dividend-earning capacity. This is favorable for companies with exempt income from investments but limited actual dividend receipt.

General Tax Planning Impact:

• Courts increasingly recognize the true nature and substance of transactions over their form
• Dispute settlement payments are now more likely to be deductible if properly documented
• However, the tax department will scrutinize settlement agreements more closely in future assessments

What Should You Do Now?

Immediate Action Items:

1. Review Your Settlement Agreements: If your company has made or is planning to make any settlement payments to resolve intellectual property disputes, review the agreements immediately. Ensure they clearly state the payment is for dispute resolution, not asset acquisition.
2. Audit Trail & Documentation: Maintain comprehensive documentation including:
   • Legal opinion confirming the settlement is compensatory
   • Correspondence showing the dispute and resolution process
   • Settlement agreement detailing why the payment is not for acquiring/improving assets
   • Internal communications showing business purpose
3. Pending Assessments: If you have pending assessments for AY 2026-27 or earlier years involving similar claims, file a fresh application with the tax authorities citing this ITAT order. Request deduction of the settlement amount as business expenditure under Section 37(1).
4. Transfer Pricing Review: If your company has related-party transactions involving patents, technology, or services, ensure your TP documentation is strengthened. The tribunal's approach suggests rigorous scrutiny of TP positions.
5. Section 14A Compliance: For companies with exempt income from investments, recalculate your Section 14A disallowance based on actual dividends earned, not potential earning capacity. File amended returns if overclaimed disallowances in AY 2026-27.

For Future Transactions: When negotiating settlement agreements, work closely with your tax advisors and legal counsel to structure the settlement documentation in a way that clearly distinguishes it from capital asset acquisition.

Key Takeaways

• Landmark Relief: Settlement payments for resolving patent infringement disputes are deductible as business expenditure under Section 37(1) ITA 2025, provided they are not payments for acquiring/improving patent rights.
• Documentation Determinative: The nature and substance of the transaction (dispute resolution vs. asset acquisition) as evidenced by the settlement agreement will determine the tax treatment. Written documentation is paramount.
• Stricter TP Scrutiny: Multinational companies should expect increased scrutiny of Transfer Pricing adjustments. The tribunal's deletion of TP adjustments signals a hardline approach on arm's length principle compliance.
• Section 14A Relief: The restriction of Section 14A disallowance to actual dividend earned (not potential earning) is favorable for investors with exempt income. Review your AY 2026-27 calculations.
• Applicability Beyond Pharma: This ruling applies to any industry settling IP disputes—IT companies, biotech firms, manufacturing units with patent licensing arrangements, and tech startups can benefit from this clarity.

Important Note: While this ITAT order is favorable for taxpayers, it is not binding on the tax department at the assessment stage. However, it carries persuasive authority and significantly strengthens your position if you face similar disputes in AY 2026-27 or subsequent assessments.

Need expert help with this? EaseValue CAs in Jaipur — WhatsApp 63677 44602